Health Trials

About this trial

The goal of this randomized controlled trial is to assess the impact of ethanol sclerotherapy on ART cycle outcomes. The main questions it aims to answer are:

1. Does ethanol sclerotherapy before ART cycle has any impact on cumulative live birth rate in patients with endometrioma? 2. Does ethanol sclerotherapy improve chronic pelvic pain, dysmenorrhea, complications during oocyte retrieval, response to ovarian stimulation (number of mature oocytes retrieved), and pregnancy loss rates?

Infertile patients with endometrioma between 4-10 cm who are scheduled for ART within 2 cycles will be randomized to ethanol sclerotherapy or no intervention.

Eligibility criteria

Qualifiers

AMH>0.3 ng/ml

unilateral/bilateral endometrioma

Endometrioma diameter 40-100 mm

Disqualifiers

3 or more IVF/embryo transfer failure

Menstrual cycle abnormalities

Male Factor infertility

Presence of uterine fibroids

Trial design

Treatments tested in this trial

  • Ethanol Sclerotherapy for Endometrioma

Treatment groups

84 Participants
are divided into 2 treatment groups

Locations

3
Başkent University Adana IVF Center Adana Turkey (Türkiye)
Ankara University School of Medicine, Department of Obstetrics and Gynecology06610, Ankara Turkey (Türkiye)
Bahçeci IVF Clinic Istanbul Turkey (Türkiye)

Sponsors and collaborators

Ankara University

Lead sponsor

Hacettepe University

Collaborator

Source ClinicalTrials.gov